Your browser doesn't support javascript.
loading
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma.
Pontarini, Elena; Murray-Brown, William James; Croia, Cristina; Lucchesi, Davide; Conway, James; Rivellese, Felice; Fossati-Jimack, Liliane; Astorri, Elisa; Prediletto, Edoardo; Corsiero, Elisa; Romana Delvecchio, Francesca; Coleby, Rachel; Gelbhardt, Eva; Bono, Aurora; Baldini, Chiara; Puxeddu, Ilaria; Ruscitti, Piero; Giacomelli, Roberto; Barone, Francesca; Fisher, Benjamin; Bowman, Simon J; Colafrancesco, Serena; Priori, Roberta; Sutcliffe, Nurhan; Challacombe, Stephen; Carlesso, Gianluca; Tappuni, Anwar; Pitzalis, Costantino; Bombardieri, Michele.
Affiliation
  • Pontarini E; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Murray-Brown WJ; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Croia C; Immuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Lucchesi D; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Conway J; Oncology R&D, Astrazeneca, Gaithersburg, Maryland, USA.
  • Rivellese F; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Fossati-Jimack L; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Astorri E; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Prediletto E; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Corsiero E; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Romana Delvecchio F; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Coleby R; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Gelbhardt E; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Bono A; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, England, UK.
  • Baldini C; University of Pisa, Rheumatology Unit, Pisa, PI, Italy.
  • Puxeddu I; Immuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Ruscitti P; Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
  • Giacomelli R; Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
  • Barone F; RRG, Institute of Inflamation and Ageing, University of Birmingham, Birmingham, UK, UK.
  • Fisher B; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Bowman SJ; RRG, Institute of Inflamation and Ageing, University of Birmingham, Birmingham, UK, UK.
  • Colafrancesco S; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Priori R; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Sutcliffe N; Dipartimento di Medicina Interna e Specilità Mediche, UOC Reumatologia, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy.
  • Challacombe S; Dipartimento di Medicina Interna e Specilità Mediche, UOC Reumatologia, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy.
  • Carlesso G; Rheumatology, Barts Health NHS Trust, London, London, UK.
  • Tappuni A; Oral Medicine, KCL Dental Institute, London, UK.
  • Pitzalis C; Early ICA Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Bombardieri M; Institute of Dentistry, Barts and The London School of Medicine and Dentistry, London, London, UK.
Ann Rheum Dis ; 79(12): 1588-1599, 2020 12.
Article in En | MEDLINE | ID: mdl-32963045
ABSTRACT

OBJECTIVES:

To explore the relevance of T-follicular-helper (Tfh) and pathogenic peripheral-helper T-cells (Tph) in promoting ectopic lymphoid structures (ELS) and B-cell mucosa-associated lymphoid tissue (MALT) lymphomas (MALT-L) in Sjögren's syndrome (SS) patients.

METHODS:

Salivary gland (SG) biopsies with matched peripheral blood were collected from four centres across the European Union. Transcriptomic (microarray and quantitative PCR) analysis, FACS T-cell immunophenotyping with intracellular cytokine detection, multicolor immune-fluorescence microscopy and in situ hybridisation were performed to characterise lesional and circulating Tfh and Tph-cells. SG-organ cultures were used to investigate functionally the blockade of T-cell costimulatory pathways on key proinflammatory cytokine production.

RESULTS:

Transcriptomic analysis in SG identified Tfh-signature, interleukin-21 (IL-21) and the inducible T-cell co-stimulator (ICOS) costimulatory pathway as the most upregulated genes in ELS+SS patients, with parotid MALT-L displaying a 400-folds increase in IL-21 mRNA. Peripheral CD4+CXC-motif chemokine receptor 5 (CXCR5)+programmed cell death protein 1 (PD1)+ICOS+ Tfh-like cells were significantly expanded in ELS+SS patients, were the main producers of IL-21, and closely correlated with circulating IgG and reduced complement C4. In the SG, lesional CD4+CD45RO+ICOS+PD1+ cells selectively infiltrated ELS+ tissues and were aberrantly expanded in parotid MALT-L. In ELS+SG and MALT-L parotids, conventional CXCR5+CD4+PD1+ICOS+Foxp3- Tfh-cells and a uniquely expanded population of CXCR5-CD4+PD1hiICOS+Foxp3- Tph-cells displayed frequent IL-21/interferon-γ double-production but poor IL-17 expression. Finally, ICOS blockade in ex vivo SG-organ cultures significantly reduced the production of IL-21 and inflammatory cytokines IL-6, IL-8 and tumour necrosis factor-α (TNF-α).

CONCLUSIONS:

Overall, these findings highlight Tfh and Tph-cells, IL-21 and the ICOS costimulatory pathway as key pathogenic players in SS immunopathology and exploitable therapeutic targets in SS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salivary Gland Diseases / Sjogren's Syndrome / Choristoma / T-Lymphocytes, Helper-Inducer / Lymphoma, B-Cell, Marginal Zone / Germinal Center Type of study: Etiology_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2020 Document type: Article Affiliation country: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salivary Gland Diseases / Sjogren's Syndrome / Choristoma / T-Lymphocytes, Helper-Inducer / Lymphoma, B-Cell, Marginal Zone / Germinal Center Type of study: Etiology_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2020 Document type: Article Affiliation country: Reino Unido
...